Aug 11, 2022
May 13, 2022
For Fiscal Year Ending Dec 31, 2021
Receive updates straight into your inbox
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, maveropepimut-S (DPX-Survivac), is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing maveropepimut-S as a monotherapy in advanced ovarian cancer, as well as a combination therapy in multiple clinical studies with Merck. IMV is also developing a DPX-based vaccine to fight against COVID-19.
130 Eileen Stubbs Suite 19 Dartmouth, Nova Scotia B3B 2C4 Canada
2875 Boulevard Laurier Delta 1, Suite 220 Québec, Québec G1V 2M2 Canada
Computershare Investor Services Inc. www.computershare.com